News

Pet food company Freshpet (NASDAQ:FRPT) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 17.6% year on year to $263.2 million. On the other hand, the company’s full-year revenue guidance of $1.14 billion at the midpoint came in 3.2% below analysts’ estimates. Its GAAP loss of $0.26 per share was significantly below analysts’ consensus estimates.

Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 3.7% year on year to $382.7 million. On the other hand, next quarter’s revenue guidance of $395 million was less impressive, coming in 5.3% below analysts’ estimates. Its non-GAAP profit of $0.41 per share was 4.9% below analysts’ consensus estimates.

Buying momentum continued in Asia and European stock markets today, but all eyes are on Jerome Powell's upcoming commentary.

Dental and medical products company Henry Schein (NASDAQ:HSIC) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $3.17 billion. Its non-GAAP profit of $1.15 per share was 3.6% above analysts’ consensus estimates.

Graco currently trades at $82.40 per share and has shown little upside over the past six months, posting a small loss of 2.6%.

What a brutal six months it’s been for West Pharmaceutical Services. The stock has dropped 34.8% and now trades at $211, rattling many shareholders. This may have investors wondering how to approach the situation.

Although the S&P 500 is down 2.4% over the past six months, Dillard’s stock price has fallen further to $359, losing shareholders 7.7% of their capital. This may have investors wondering how to approach the situation.